These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis. McCall LI; Zhang WW; Ranasinghe S; Matlashewski G Vaccine; 2013 Feb; 31(10):1420-5. PubMed ID: 23219435 [TBL] [Abstract][Full Text] [Related]
5. In vivo selection for Leishmania donovani miniexon genes that increase virulence in Leishmania major. Zhang WW; Matlashewski G Mol Microbiol; 2004 Nov; 54(4):1051-62. PubMed ID: 15522086 [TBL] [Abstract][Full Text] [Related]
6. Comparative in vivo expression of amastigote up regulated Leishmania genes in three different forms of Leishmaniasis. Sharma P; Gurumurthy S; Duncan R; Nakhasi HL; Salotra P Parasitol Int; 2010 Jun; 59(2):262-4. PubMed ID: 19963076 [TBL] [Abstract][Full Text] [Related]
7. Expression of a Leishmaniadonovani nucleotide sugar transporter in Leishmaniamajor enhances survival in visceral organs. Zhang WW; Chan KF; Song Z; Matlashewski G Exp Parasitol; 2011 Dec; 129(4):337-45. PubMed ID: 21978449 [TBL] [Abstract][Full Text] [Related]
8. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. Rachamim N; Jaffe CL J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215 [TBL] [Abstract][Full Text] [Related]
9. Evidence that a naturally occurring single nucleotide polymorphism in the RagC gene of Leishmania donovani contributes to reduced virulence. Lypaczewski P; Zhang WW; Matlashewski G PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009079. PubMed ID: 33621241 [TBL] [Abstract][Full Text] [Related]
10. An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient. Routaray CB; Kumar A; Sundar S; Sathe G; Pawar H; Pai K Acta Parasitol; 2022 Jun; 67(2):687-696. PubMed ID: 35020128 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection. Zhang WW; Mendez S; Ghosh A; Myler P; Ivens A; Clos J; Sacks DL; Matlashewski G J Biol Chem; 2003 Sep; 278(37):35508-15. PubMed ID: 12829719 [TBL] [Abstract][Full Text] [Related]
12. Tissue Specific Dual RNA-Seq Defines Host-Parasite Interplay in Murine Visceral Leishmaniasis Caused by Leishmania donovani and Leishmania infantum. Forrester S; Goundry A; Dias BT; Leal-Calvo T; Moraes MO; Kaye PM; Mottram JC; Lima APCA Microbiol Spectr; 2022 Apr; 10(2):e0067922. PubMed ID: 35384718 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Al-Abdely HM; Graybill JR; Loebenberg D; Melby PC Antimicrob Agents Chemother; 1999 Dec; 43(12):2910-4. PubMed ID: 10582881 [TBL] [Abstract][Full Text] [Related]
15. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection. Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224 [TBL] [Abstract][Full Text] [Related]
16. An imported case of cutaneous leishmaniasis caused by Leishmania (Leishmania) donovani in Japan. Ito K; Takahara M; Ito M; Oshiro M; Takahashi K; Uezato H; Imafuku S J Dermatol; 2014 Oct; 41(10):926-8. PubMed ID: 25228325 [TBL] [Abstract][Full Text] [Related]
17. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Melby PC; Yang J; Zhao W; Perez LE; Cheng J Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143 [TBL] [Abstract][Full Text] [Related]
18. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. Al-Abdely HM; Graybill JR; Bocanegra R; Najvar L; Montalbo E; Regen SL; Melby PC Antimicrob Agents Chemother; 1998 Oct; 42(10):2542-8. PubMed ID: 9756753 [TBL] [Abstract][Full Text] [Related]
19. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? McMahon-Pratt D; Alexander J Immunol Rev; 2004 Oct; 201():206-24. PubMed ID: 15361243 [TBL] [Abstract][Full Text] [Related]
20. Leishmania donovani: impairment of the cellular immune response against recombinant ornithine decarboxylase protein as a possible evasion strategy of Leishmania in visceral leishmaniasis. Yadav A; Amit A; Chaudhary R; Chandel AS; Mahantesh V; Suman SS; Singh SK; Dikhit MR; Ali V; Rabidas V; Pandey K; Kumar A; Das P; Bimal S Int J Parasitol; 2015 Jan; 45(1):33-42. PubMed ID: 25449949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]